Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+3.96%
-11.25%
-1.22%
+13.45%
Most Trending
+3.96%
-11.25%
-1.22%
+13.45%
Top.GainersTop.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
04 Dec 2025$SNCR Synchronoss Technologies exploded into the midday spotlight as Lumine Group, backed by Constellation Software, announced a definitive all-cash acquisition that gives shareholders a clear exit value. The certainty of cash on the table, combined with an outsized volume surge far above its daily norm, lit a fire under the stock and pulled in both event-driven traders and arbitrage-focused funds chasing the spread. The move is less about speculation and more about deal confidence, which usually keeps momentum sticky throughout the session.
$PATH UiPath has quietly turned into a momentum darling, logging its fifth straight positive session while trading at more than double its average volume. The renewed interest follows fresh visibility from its earnings presentation and a broader resurgence of appetite for AI automation plays. Traders appear to be rotating back into software names with tangible enterprise use cases, and UiPath blend of AI and operational efficiency is benefitting from that narrative in real time.
$AXGN Axogen surged after receiving FDA approval for its AVANCE Nerve Allograft for peripheral nerve repair, a milestone that significantly de-risks its regulatory path and expands its commercial runway. Medical device approvals tend to bring in longer-term institutional interest and the volume spike suggests this is not just a short-lived trade but a potential repricing of the addressable market and future revenue expectations.
$ASTS AST SpaceMobile extended its strong run as traders latched onto renewed enthusiasm around its satellite constellation vision and the long-term implications of space-based mobile connectivity. With volume tracking above average and sentiment fueled by bullish thesis chatter, the stock is benefiting from a blend of speculative energy and conviction buying tied to its ambitious infrastructure buildout in orbit.
$NUTX Nutex Health jumped after announcing the extension of its $25 million share repurchase program through March 2026, reinforcing management confidence in the valuation and cash flow stability. Buyback extensions often act as a psychological floor for the stock and the move shows traders stepping in ahead of that implied support, despite volume still running slightly below its historical average.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
